Novo Nordisk (ADR) (NVO)

Novo Nordisk has lost roughly a tenth of its value in the past month.

What is going on right now?

The stock has drifted below where it sat over both the past couple of months and the past several months, on notably quiet trading. Reports suggest an upcoming Federal Reserve decision week could shift how the market prices healthcare companies.

How is the business itself doing?

Novo Nordisk makes most of its money from its weight-loss and diabetes drugs. It keeps about 82 cents of every dollar after production costs, but its earnings fell about 21% compared to a year ago even as sales crept up slightly.

What stands out?

Nearly all of its revenue depends on one family of drugs, the GLP-1 treatments. Eli Lilly is pushing hard on the same category with competing pills and data.

What comes next?

Novo Nordisk's next earnings report lands on November 4, the first chance to see whether the newer oral versions of its drugs are changing the sales picture.